Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 59OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Head and Neck Neoplasms 5Stomatitis 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Mucositis 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Diseases 1Glioblastoma 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1

Interventions

Gemcitabine 12Cisplatin 11pembrolizumab 6Docetaxel 5Capecitabine 5camrelizumab 4Injections 4toripalimab 3spartalizumab 3penpulimab 2famitinib 2SHR-1701 2Carboplatin 218-O-demethylcervinomycin A2 2tislelizumab 1icotinib 1donafenib 1cc-486 1Valganciclovir 1Radiotherapy, Intensity-Modulated 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Medicare Part B 1Ipilimumab 1Immunotherapy 1Fluorouracil 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Nasopharyngeal Carcinoma × Radiotherapy, Intensity-Modulated × Clear all
NCT04895345 2024-09-26

A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
25 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡